$SHILPAMED : CO. ENTERS STRATEGIC EQUITY PARTNERSHIP WITH GATE2BRAIN FOR 30.4% STAKE; FOCUS ON ADVANCING BRAIN CANCER THERAPY G2B-002 WITH ORPHAN DRUG DESIGNATION FROM US FDA AND EMA.
#WatchOutFor
1,117 likes·83 comments
Popular topics to explore
$SHILPAMED : CO. ENTERS STRATEGIC EQUITY PARTNERSHIP WITH GATE2BRAIN FOR 30.4% STAKE; FOCUS ON ADVANCING BRAIN CANCER THERAPY G2B-002 WITH ORPHAN DRUG DESIGNATION FROM US FDA AND EMA.